Skip to main content

Kestrel Consultancy Group

University College Dublin

Project Sonic is currently at phase two of an investigation into the practicalities and viabilities 3D Structured hollow microneedle systems

Phase One: Market Investigation of UCD Microneedle Technology
  • Microneedle Potential Therapy Areas
  • Characterisation of UCD microneedle technology

Completed

Phase Two: – Market exploration and partnership development
  • Refine and consolidate the unmet needs in discussion with solution providers
  • External review with KOLs of the following:
    • User Requirements Specification and Functional Requirements Specification
    • Concept design
    • Technical risks and mitigation measures

Underway

Needle phobia and patient injection pain are known issues with injected drug therapies.

These issues became particularly acute during the COVID-19 vaccination programme. Microneedles address many of the shortcomings of injection systems with additional benefits including preventing needle stick injuries.

Kestrel is working on phase 2 of this UCD to identify specific clinical applications and developing routes to market with commercial partners to bring this exciting and much-needed technology to patients.

Why consider microneedles instead of traditional intradermal injections?

Needle phobia (50% of children; 25% of adolescents; 10% of general population)

  • Reduced pain due to <1.0mm needles
  • Reduced risk of needle stick injuries
  • Enables patient self-administration
  • Extends drug delivery duration
  • Manages peak drug concentration and limits saturation

Common misconceptions with regards to use of microneedles

  • Microneedles are expensive – X
  • Microneedles can only deliver a very small dose volumes – X
  • Microneedles can only be used for topical treatments – X
  • Microneedles are brittle – X
  • Microneedles cannot be manufactured in large volumes – X
  • Microneedles are only available in small arrays – X
  • Microneedles are only usable with low viscosity formulas – X

Think again!

  • Moulded hollow microneedle design reduces costs and unlocks high-volume manufacture
  • Wide choice of material options reduces risk of brittle material fragments, lowers Cost of Goods and offers flexible substrate options
  • 3D needle design injecting at different skin depths reduces drug saturation and increases intradermal drug absorption rate, increasing delivery rates
  • Large and scalable needle array (>100) enables larger injection volumes over wider area
  • Multiple parallel flow channels allow delivery of viscous, high molecular weight compounds without damaging high shear rates
  • Suitable for multiple topical and systemic drug delivery regimes